Parabilis Medicines Initiates Dose-Ranging Clinical Cohort Evaluating Zolucatetide In Patients With Familial Adenomatous Polyposis As Part Of Ongoing Phase 1/2 Clinical Trial

Parabilis Medicines (NASDAQ: PBLS) has initiated a dose-ranging clinical cohort to evaluate zolucatetide in patients with familial adenomatous polyposis (FAP) as part of its ongoing Phase 1/2 clinical trial. Zolucatetide is the company's lead investigational peptide and is the first direct inhibitor of the β-catenin:TCF interaction, which is crucial in the development of various cancers. This new cohort builds on promising early clinical evidence observed in patients with FAP and desmoid tumors.